Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'expensive' on P/E, undervalued on EV/EBITDA, underpriced on P/F
Target Price
The average target price of MDP.TO is 6.9 and suggests 142% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell